{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:45Z","timestamp":1792552305754,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,25]],"date-time":"2014-01-25T00:00:00Z","timestamp":1390608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40265-014-0178-8","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T03:24:46Z","timestamp":1390533886000},"page":"263-271","source":"Crossref","is-referenced-by-count":149,"title":["Ibrutinib: First Global Approval"],"prefix":"10.1007","volume":"74","author":[{"given":"Fiona","family":"Cameron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,25]]},"reference":[{"key":"178_CR1","unstructured":"Lymphoma Research Foundation. Non-Hodgkin lymphoma (NHL). 2012. http:\/\/www.lymphoma.org . Accessed 9 Nov 2013."},{"issue":"1","key":"178_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1922\u20132001. Blood. 2006;107(1):265\u201376.","journal-title":"Blood"},{"issue":"10","key":"178_CR3","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1172\/JCI64101","volume":"122","author":"G Gaidano","year":"2012","unstructured":"Gaidano G, Fo\u00e0 R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432\u20138.","journal-title":"J Clin Invest."},{"issue":"11","key":"178_CR4","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S1470-2045(10)70210-2","volume":"11","author":"N Murawski","year":"2010","unstructured":"Murawski N, Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol. 2010;11(11):1074\u201385.","journal-title":"Lancet Oncol."},{"key":"178_CR5","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2165\/11594630-000000000-00000","volume":"71","author":"JE Chang","year":"2011","unstructured":"Chang JE, Kahl BS. Current status of targeted therapies for mantle cell lymphoma. Drugs. 2011;71:2307\u201326.","journal-title":"Drugs."},{"issue":"9","key":"178_CR6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.clinthera.2013.08.004","volume":"35","author":"AV Danilov","year":"2013","unstructured":"Danilov AV. Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther. 2013;35(9):1258\u201370.","journal-title":"Clin Ther."},{"issue":"1","key":"178_CR7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","volume":"31","author":"A Wiestner","year":"2013","unstructured":"Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128\u201330.","journal-title":"J Clin Oncol."},{"key":"178_CR8","unstructured":"Pharmacyclics, Inc. ImbruvicaTM (ibrutinib) capsules for oral use; US prescribing information. 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/205552s000lbl.pdf . Accessed 10 December 2013."},{"issue":"1","key":"178_CR9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88\u201394.","journal-title":"J Clin Oncol."},{"key":"178_CR10","unstructured":"Pharmacyclics, Inc. New drug application filing for ibrutinib accepted in two B-cell malignancies by the U.S. FDA [media release]. Aug 29 2013. http:\/\/www.pharmacyclics.com ."},{"key":"178_CR11","unstructured":"Pharmacyclics, Inc. New drug application for ibrutinib submitted to the U.S. FDA [media release]. Jul 10 2013. http:\/\/www.pharmacyclics.com ."},{"key":"178_CR12","unstructured":"Celera Corp. Celera Corporation separates from Applera Corporation [media release]. Jul 1 2008. http:\/\/www.celera.com ."},{"key":"178_CR13","unstructured":"Pharmacyclics, Inc. Celera Genomics announces sale of therapeutic programs to Pharmacyclics [media release]. Apr 10 2006. http:\/\/www.pharmacyclics.com ."},{"key":"178_CR14","unstructured":"Celera Genomics. Celera Genomics reports first quarter fiscal 2006 results [media release]. Oct 27 2005. http:\/\/www.celera.com ."},{"key":"178_CR15","unstructured":"Quest Diagnostics Inc. Quest Diagnostics successfully completes acquisition of Celera [media release]. May 17 2011. http:\/\/www.questdiagnostics.com ."},{"key":"178_CR16","unstructured":"Pharmacyclics, Inc. Pharmacyclics announces collaboration with the National Cancer Institute to develop its novel Btk Inhibitor, PCI-32765 in hematologic malignancies [media release]. Aug 9 2011. http:\/\/www.pharmacyclics.com ."},{"key":"178_CR17","unstructured":"WuXi PharmaTech Inc. WuXi Pharma to partner with Pharmacyclics [media release]. Nov 15 2013. http:\/\/www.wuxiapptec.com ."},{"issue":"15","key":"178_CR18","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539\u201349.","journal-title":"Blood."},{"key":"178_CR19","unstructured":"Honigberg LA, Smith AM, Loury DJ. A clinical trial of the Bruton\u2019s tyrosine kinase inhibitor PCl-32765 in naturally occurring canine lymphoma [abstract no. 3740]. In: 100th Annual Meeting of the American Association for Cancer Research; Apr 18\u201322 2009; Denver."},{"key":"178_CR20","unstructured":"Honigberg L, Smith A, Chen J, et al. PCL-31523: an irreversible inhibitor of Bruton\u2019s tyrosine kinase that disrupts B cell receptor signaling, is cytotoxic to B cell lymphomas, and is active in an animal arthritis model [abstract no. 5398]. In: 98th Annual Meeting of the American Association for Cancer Research; Apr 14\u201318 2007; Los Angeles."},{"key":"178_CR21","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S, Chen SS, Buggy JJ, et al. Bruton\u2019s tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182\u20139.","journal-title":"Blood."},{"key":"178_CR22","unstructured":"Nimbus Discovery. Nimbus Discovery IRAK4 inhibitors demonstrate synergistic effects with BTK iInhibitor ibrutinib [media release]. Dec 9 2012. http:\/\/www.nimbusdiscovery.com ."},{"key":"178_CR23","doi-asserted-by":"crossref","unstructured":"Elias L, Chen J, Buggy J. BTK inhibitor ibrutinib inhibits breast cancer growth by inhibiting ErbB2 kinase [abstract no. C258]. In: 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 19\u201323 2013, Boston.","DOI":"10.1158\/1535-7163.TARG-13-C258"},{"key":"178_CR24","doi-asserted-by":"crossref","unstructured":"Lobe CG, Allain MJ, Yang W. Activity of BTK and HDAC inhibitors alone and in combination in a mouse model of non-small cell lung cancer [abstract no. C243]. In: 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 19\u201323 2013, Boston.","DOI":"10.1158\/1535-7163.TARG-13-C243"},{"key":"178_CR25","doi-asserted-by":"crossref","unstructured":"Vij R, Chang BY, Berdeja JG, et al. Early changes in cytokines, chemokines and indices of bone metabolism in a phase 2 study of the Bruton tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765) in patients with relapsed or relapsed\/refractory multiple myeloma (MM) [abstract no. 653]. In: 54th Annual Meeting of the American Society of Hematology; Dec 8\u201311 2012, Atlanta.","DOI":"10.1182\/blood.V120.21.4039.4039"},{"key":"178_CR26","unstructured":"Nathan F, Jeff S, Sonali S, et al. A phase I trial of BTK inhibitor PCI-32765 in patients with relapsed non-Hodgkin\u2019s lymphoma: evidence of antitumor activity [abstract no. 0893]. In: 15th Congress of the European Haematology Association; Jun 10\u201313 2010, Barcelona."},{"issue":"6","key":"178_CR27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med."},{"key":"178_CR28","first-page":"98","volume":"31","author":"A Wiestner","year":"2013","unstructured":"Wiestner A, Farooqui M, Valdez J, et al. Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukaemia patients with 17p deletion. Hematol Oncol. 2013;31:98.","journal-title":"Hematol Oncol."},{"issue":"1","key":"178_CR29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342.","journal-title":"N Engl J Med."},{"key":"178_CR30","doi-asserted-by":"crossref","unstructured":"Brown JR, Barrientos JC, Barr PM, et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed\/refractory CLL\/SLL: final results of a phase 1b study [abstract no. 525]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7\u201310 2013; New Orleans.","DOI":"10.1182\/blood.V122.21.525.525"},{"key":"178_CR31","first-page":"193","volume":"31","author":"JA Burger","year":"2013","unstructured":"Burger JA, Keating MJ, Wierda WG, et al. Efficacy and safety of ibrutinib in combination with rituximab in high-risk CLL patients. Hematol Oncol. 2013;31:193\u20134.","journal-title":"Hematol Oncol."},{"key":"178_CR32","doi-asserted-by":"crossref","unstructured":"Burger JA, Keating MJ, Wierda WG, et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induced a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a phase II trial in 40 patients [abstract no. 675]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7\u201310 2013; New Orleans.","DOI":"10.1182\/blood.V122.21.675.675"},{"key":"178_CR33","doi-asserted-by":"crossref","unstructured":"Farooqui M, Aue G, Valdez J, et al. Single agent ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p [abstract no. 673]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7\u201310 2013; New Orleans.","DOI":"10.1182\/blood.V122.21.673.673"},{"key":"178_CR34","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Furman RR, Fowler N, et al. The Bruton\u2019s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) monotherapy demonstrates long-term safety and durability of response in chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) patients in an open-label extension study [abstract no. 4163]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7\u201310 2013; New Orleans.","DOI":"10.1182\/blood.V122.21.4163.4163"},{"key":"178_CR35","doi-asserted-by":"crossref","unstructured":"Wilson WH, Gerecitano JF, Goy A, et al. The Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract no. 686]. In: 54th Annual Meeting of the American Society of Hematology; Dec 8\u201311 2012, Atlanta.","DOI":"10.1182\/blood.V120.21.686.686"},{"key":"178_CR36","doi-asserted-by":"crossref","unstructured":"deVos S, Wilson WH, Gerecitano JF, et al. The Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed\/refractory (RR) DLBCL: interim phase 2 results [abstract no. S1180]. In: 18th Congress of the European Haematology Association; Jun 13\u201316 2013, Stockholm.","DOI":"10.1182\/blood.V120.21.686.686"},{"key":"178_CR37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/hon.2071","volume":"31","author":"S Treon","year":"2013","unstructured":"Treon S, Tripsas C, Yang G, et al. A prospective, multicentre, phase II study of the Bruton\u2019s tyrosine kinase inhibitor ibrutinib in patients with relapsed and refractory Waldenstrom\u2019s macroglobulinemia [abstract no. 067]. Hematol Oncol. 2013;31:119.","journal-title":"Hematol Oncol."},{"key":"178_CR38","unstructured":"Treon SP, Tripsas K, Yang G, et al. A prospective multicenter study of the Bruton\u2019s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom\u2019s macroglobulimemia [abstract no. 251]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7\u201310 2013, New Orleans."},{"key":"178_CR39","unstructured":"Abbott, Inc. Abbott to collaborate with Janssen and Pharmacyclics on development of companion test for investigational leukemia therapy [media release]. Feb 21 2013. http:\/\/www.abbott.com ."},{"key":"178_CR40","unstructured":"US Food and Drug Administration. Imbruvica. 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2013\/205552Orig1s000ltr.pdf . Accessed 9 December 2013."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0178-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0178-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T20:43:55Z","timestamp":1688935435000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0178-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,25]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["178"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0178-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,25]]}}}